Total Migraine Freedom, a Potential Primary Endpoint to Assess Acute Treatment in Migraine: Comparison to the Current FDA Requirement Using the Complete Rizatriptan Study DatabaseRODGERS, Anthony J; HUSTAD, Carolyn M; CADY, Roger K et al.Headache. 2011, Vol 51, Num 3, pp 356-368, issn 0017-8748, 13 p.Article

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trialsERON, Joseph J; YOUNG, Benjamin; KUMAR, Princy N et al.Lancet (British edition). 2010, Vol 375, Num 9712, pp 396-407, issn 0140-6736, 12 p.Article

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trialLENNOX, Jeffrey L; DEJESUS, Edwin; BARNARD, Richard J. O et al.Lancet (British edition). 2009, Vol 374, Num 9692, pp 796-806, issn 0140-6736, 11 p.Article

Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/ Emtricitabine for Treatment-Naive Human Immunodeficiency Virus-1-Infected Patients: 156-Week Results From STARTMRKROCKSTROH, Jiirgen K; LENNOX, Jeffrey L; DINUBILE, Mark J et al.Clinical infectious diseases. 2011, Vol 53, Num 8, pp 807-816, issn 1058-4838, 10 p.Article

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trialERON, Joseph; ROCKSTROH, Jürgen K; NELSON, Mark et al.Lancet. Infectious diseases (print). 2011, Vol 11, Num 12, pp 907-915, issn 1473-3099, 9 p.Article